InsidersTradesSigma
Follow the Trillium Therapeutics Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Health Care sector, Trillium Therapeutics Inc. has recorded 6 public disclosures. The latest transaction was reported on 19 November 2021 (Disposition). Among the most active insiders: Uger Robert. All data is openly available.
6
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
2 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 November 2021
Declarations6 total
75 sharesCommon SharesSEC:0001104659-21-141749:0
5,736,363 shares0Common SharesSEC:0001209191-21-065762:0
3,646 shares@ US$0.303933.2% of flowCommon SharesSEC:0001062993-21-006419:0
3,646 shares@ US$0.31533.3% of flowCommon SharesSEC:0001062993-21-005487:0
87,500 shares@ US$0.4462100.0% of flowCommon SharesSEC:0001062993-21-004511:0
3,646 shares@ US$0.31333.4% of flowCommon SharesSEC:0001062993-21-004390:0
6 of 6 declarations
About Trillium Therapeutics Inc.
Trillium Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. It concentrates on immunological approaches to enhance patient outcomes.
